利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.015 秒)

    Modular targeted therapeutic agents and methods of making same
    1.
    发明授权
    Modular targeted therapeutic agents and methods of making same 有权

    公开(公告)号：US11633474B2

    公开(公告)日：2023-04-25

    申请号：US16231099

    申请日：2018-12-21

    申请人： PROTEONOVA, INC.

    发明人： Richard B. Williams ,  Robert Guerrero

    IPC分类号： C12N15/10 ,  G01N33/531 ,  C12N15/62 ,  C12P19/34 ,  C07K14/00 ,  A61K39/395 ,  G01N33/68 ,  C07K16/30 ,  C40B30/04

    摘要： Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.

    MODULAR TARGETED THERAPEUTIC AGENTS AND METHODS OF MAKING SAME
    5.
    发明申请
    MODULAR TARGETED THERAPEUTIC AGENTS AND METHODS OF MAKING SAME 审中-公开
    模块化针对性治疗剂及其制备方法

    公开(公告)号：US20130183312A1

    公开(公告)日：2013-07-18

    申请号：US13791615

    申请日：2013-03-08

    申请人： Proteonova, Inc.

    发明人： Richard B. Williams ,  Robert Guerrero

    IPC分类号： A61K39/395

    CPC分类号： A61K39/395 ,  C12N15/1062 ,  C12N15/1068 ,  C12N15/1075 ,  C12P19/34 ,  C40B30/04 ,  G01N33/531 ,  G01N33/6845

    摘要： Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.

    摘要翻译： 本文提供了制备靶向治疗剂的方法。 在几个实施方案中，治疗剂针对可溶性试剂，例如毒素，毒液和/或改变生理生物学途径的其它因素，以及使用这些治疗剂治疗患者或患者群体以减少，消除或失活有害可溶性的方法 这些患者或患者群体接触过的药物。 在几个实施方案中，治疗剂针对患者特异性疾病标记物。 在几个实施方案中，所述方法包括筛选包含与其同源mRNA相连的蛋白质的文库，以鉴定结合病变细胞的mRNA-蛋白质对，从鉴定的mRNA-蛋白质对分离一种或多种蛋白质，并将分离的蛋白质 ）到治疗剂。

    METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS DIRECTED TO SOLUBLE TARGETS
    7.
    发明申请
    METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS DIRECTED TO SOLUBLE TARGETS 审中-公开
    制造针对可溶性目标的针对性治疗药物的方法

    公开(公告)号：US20130129769A1

    公开(公告)日：2013-05-23

    申请号：US13738861

    申请日：2013-01-10

    申请人： PROTEONOVA, INC.

    发明人： Richard B. Williams ,  Robert Guerrero

    IPC分类号： A61K39/00 ,  C12N15/10

    CPC分类号： C12P19/34 ,  C12N15/1068 ,  C12N15/1075

    摘要： Provided herein are methods for making targeted therapeutics that target soluble agents such as toxins, venoms, and factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments the targeted therapeutics comprise a portion that interacts with a soluble agent of interest and a second portion that interacts with a subject's immune system, which enables treatment of a patient for exposure to the soluble agent.

    摘要翻译： 本文提供了制备靶向治疗剂的方法，其靶向可溶性试剂，例如毒素，毒液和改变生理生物学途径的因子，以及使用这些治疗剂治疗患者或患者群体以减少，消除或灭活有害可溶性物质的方法， 已经暴露了这样的患者或患者群体。 在几个实施方案中，靶向治疗剂包含与感兴趣的可溶性药物相互作用的部分和与受试者的免疫系统相互作用的第二部分，其能够治疗患者暴露于可溶性试剂。